Piper Sandler analyst Adam Maeder maintains Zynex (NASDAQ:ZYXI) with a Neutral and raises the price target from $7 to $10.
Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott’s Next-Gen Abalation Catheter
Stereotaxis Inc (NYSE: STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE: ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' <